Patient preference doesn't affect chemo in advanced CRC

September 21, 2012
Patient preference doesn't affect chemo in advanced CRC
For patients with metastatic colorectal cancer, most patients are treated with chemotherapy, even if they express negative or marginal preferences, according to a study published online Sept. 12 in Cancer.

(HealthDay)—For patients with metastatic colorectal cancer (mCRC), most patients are treated with chemotherapy, even if they express negative or marginal preferences, according to a study published online Sept. 12 in Cancer.

S. Yousuf Zafar, M.D., M.H.S., of the Duke Cancer Institute in Durham, N.C., and colleagues conducted a involving 702 patients with mCRC to determine how patient preferences guide the course of palliative .

Overall, 91 percent of patients were treated by a medical oncologist, and 82 percent of these received chemotherapy. The researchers found that patients aged 65 to 75 years or 75 years and older were less likely to visit an oncologist, as were those who were too unwell to complete their own survey. Patients who were 75 years or older with moderate or severe comorbidities or patients who were too unwell to complete their own survey were less likely to receive chemotherapy. Patients tended to receive chemotherapy even when they felt that treatment would not extend their lives (90 percent) or help them with their cancer-related problems (89 percent), and even when they stated a preference to focus on comfort rather than extending their life (90 percent).

"In summary, in the palliative setting were not always congruent with stated preferences and beliefs regarding chemotherapy," the authors write. "The vast majority of patients who expressed negative or marginal preferences or beliefs regarding chemotherapy still received chemotherapy. Patient preferences and beliefs were not associated with the intensity or number of chemotherapy regimens received."

Several authors disclosed financial ties to the .

Explore further: ASCO: Continuing avastin with 2nd-line chemo ups survival

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

ASCO: Continuing avastin with 2nd-line chemo ups survival

June 5, 2012
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...

Certain head and neck cancer patients benefit from second round of treatment

June 13, 2011
A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck ...

Chemotherapy is as effective before breast cancer surgery as after

September 8, 2011
Whether chemotherapy is given before or after breast-conserving therapy (BCT) does not have an impact on long-term local-regional outcomes, suggesting treatment success is due more to biologic factors than chemotherapy timing, ...

Breast cancer survivors struggle with cognitive problems several years after treatment

December 12, 2011
A new analysis has found that breast cancer survivors may experience problems with certain mental abilities several years after treatment, regardless of whether they were treated with chemotherapy plus radiation or radiation ...

Nelarabine plus chemo viable in children with T-cell ALL

June 29, 2012
(HealthDay) -- Treatment of children with newly-diagnosed T-cell acute lymphoblastic leukemia (T-ALL) with nelarabine, in addition to an intensive Berlin-Frankfurt-Münster (BFM) 86-based chemotherapy regimen, is feasible ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.